ArticleInternational journal of clinical and experimental pathology2015
The role of EphB4 and IGF-IR expression in breast cancer cells.
Article in International journal of clinical and experimental pathology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 12 citations in OpenAlex.
- Trial in progress: phase I study of non-viral gene-modified CAR-T cell therapy for malignant solid tumors expressing EPHB4 receptor (CARTiEr).Frontiers in oncology · 2025Article
- Vandetanib drives growth arrest and promotes sensitivity to imatinib in chronic myeloid leukemia by targeting ephrin type-B receptor 4.Molecular oncology · 2022Article
- Review
- Current Advances inFrontiers in pharmacology · 2021Review
- Evaluation of EphB4 as Target for Image-Guided Surgery of Breast Cancer.Pharmaceuticals (Basel, Switzerland) · 2020Article
- EPHB4 is a therapeutic target in AML and promotes leukemia cell survival via AKT.Blood advances · 2017Article
- Natural Products for Chemoprevention of Breast Cancer.Journal of cancer prevention · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveto investigate the role of EphB4 and IGF-1R in the proliferation and migration of breast cancer.
methodsThe relative mRNA levels of EphB4 were measured by RT-PCR. The proliferation of the cells was determined by MTT assay, and cells migration and invasive ability was analyzed using the scratch migration assay.
resultsThe expression of EphB4 in control group was significantly decreased when compared with IGF-I group (P<0.001). The expression of EphB4 in IGF-I+LY and LY group were lower than that of the control group (P<0.001).The cell proliferation and migration ability of the cells in IGF-I group increased significantly compared to the cells in the control group (P<0.001), while the cells in IGF-1+LY group and LY group showed a decreased proliferation and migration ability compared to the control group (P<0.001).
conclusionIGF-IR might be a upstream gene of EphB4. Besides, higher expression of EphB4 shows increased tumor proliferation and migration in breast cells. The study of EphB4 upstream gene and signaling pathway can provide more targeted anti-tumor point selection for targeted therapy.
Indexed as
Identifiers
26191333PMC4503204W1172681526What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.